Chief Medical Officer Directorate
Pharmacy and Medicines Division

Scottish Government
Riaghaltas na h-Alba
gov.scot

T: 0131-244-2528
E: irene.fazakerley@gov.scot

IMMEDIATE MESSAGE TO:

1. Directors of Pharmacy
2. Medical Directors NHS Boards

24 October 2024

Dear Healthcare Professional,

DRUG ALERT CLASS 3 UPDATE TO DRUG ALERT 46 2024 – CLASS 3 MEDICINES RECALL – ACTION WITHIN 5 DAYS – GLENMARK PHARMACEUTICALS EUROPE LTD – CYANOCOBALAMIN 50MCG TABLETS

Please see drug alert for onward transmission as below

Could all Directors of Pharmacy please forward this alert to:-

- Community Pharmacists
- Hospital Pharmacists
- Primary Care Pharmacists

Please could Medical Directors arrange to forward this alert on to:-

- General Practitioners
- Accident & Emergency Departments
- Directors of Public Health
- Relevant Clinics
- Chief Executives of NHS Board

Thank you for your co-operation.

Yours sincerely

IRENE FAZAKERLEY
Medicines Policy Team

Medicines & Healthcare products Regulatory Agency

MEDICINES RECALL

CLASS 3 MEDICINES RECALL

Action Within 48 hours
Pharmacy/Wholesaler Level Recall

Date: 24 October 2024 EL (24)A/46 Our Ref: DMRC-31522269

Dear Healthcare Professional,

Important update
This recall notification has been updated since its initial publication on 3rd of October 2024 to include the correct batch information for Cyanocobalamin 50 mcg Tablets, batch 17231510A. Glenmark Pharmaceuticals Europe Ltd. erroneously provided incorrect information pertaining the expiry date of batch 17231510A and have ensured that all other batch information is correct. Please ensure that appropriate action is taken to ensure this batch is recalled.

Glenmark Pharmaceuticals Europe Ltd

Cyanocobalamin 50 mcg Tablets **PL 25258/0369**

SNOMED Code

Batch No	Expiry Date	Pack Size	First Distributed
17231378A	30-Nov-2024	50	01-Oct-2023
17231510A	31-Dec-2024	50	14-Mar-2024
17231511A	31-Dec-2024	50	17-Apr-2024

Active Pharmaceutical Ingredient: Cyanocobalamin

Brief description of the problem
Glenmark Pharmaceuticals Europe Ltd is recalling the above batches of products as stability testing and retesting results have reported that levels of Unknown Impurity do not conform with the specification limit in the Marketing Authorization of the product. The recall is at pharmacy and wholesaler level.

Advice for healthcare professionals
Stop supplying the above batch immediately. Quarantine all remaining stock and return it to your supplier using your supplier's approved process.

Advice for patients
No further action is required by patients as this is a Pharmacy and Wholesaler level recall. Patients should continue to take medicines from these batches as prescribed by your healthcare professional.

Patients who experience adverse reactions or have any questions about the medication, should seek medical attention. Any suspected adverse reactions should also be reported via the MHRA Yellow Card scheme.

Further Information
For medical information enquiries please use the following options by phone +44 8004 580 383 or email medical_information@glenmarkpharma.com

For stock control enquiries please email orders.uk@glenmarkpharma.com

Medicines & Healthcare products Regulatory Agency

Recipients of this Medicines Recall should bring it to the attention of relevant contacts by copy of this notice. NHS regional teams are asked to forward this to community pharmacists and dispensing general practitioners for information.

Yours faithfully

Defective Medicines Report Centre
10 South Colonnade
Canary Wharf
London
E14 4PU
Telephone +44 (0)20 3080 6574
DMRC@mhra.gov.uk